Transcode Therapeutics Stock Performance

RNAZ Stock  USD 8.58  0.40  4.45%   
The entity has a beta of 0.34, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, Transcode Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Transcode Therapeutics is expected to be smaller as well. Transcode Therapeutics right now has a risk of 6.15%. Please validate Transcode Therapeutics maximum drawdown, as well as the relationship between the daily balance of power and period momentum indicator , to decide if Transcode Therapeutics will be following its existing price patterns.

Risk-Adjusted Performance

Soft

 
Weak
 
Strong
Over the last 90 days Transcode Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong basic indicators, Transcode Therapeutics is not utilizing all of its potentials. The latest stock price disturbance, may contribute to short-term losses for the investors. ...more

Actual Historical Performance (%)

One Day Return
13.81
Five Day Return
(8.53)
Year To Date Return
34.73
Ten Year Return
(100.00)
All Time Return
(100.00)
Last Split Factor
1:28
Last Split Date
2025-05-15
1
Goldman Sachs Group Inc Significantly Reduces Holdings in TransCode Therapeutics Inc - GuruFocus
11/14/2025
2
TransCode Therapeutics Expands Executive Team with Appointment of Dr. Michel Janicot as Senior Development Officer
11/17/2025
3
Acquisition by Robert Dudley of 135000 shares of Transcode Therapeutics subject to Rule 16b-3
11/28/2025
4
TransCode Therapeutics and Quantum Leap Healthcare Collaborative Launch a Phase 2a dose-expansion trial with TTX-MC138, following positive readouts from TransCo...
12/11/2025
5
Insider Trading
12/19/2025
6
TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors
12/22/2025
7
Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
01/07/2026
8
Market Catalysts Is TransCode Therapeutics Inc a speculative investment - Quarterly Portfolio Report Fast Gain Swing Alerts - baoquankhu1.vn
01/21/2026
Begin Period Cash Flow2.8 M
Total Cashflows From Investing Activities-21.8 K

Transcode Therapeutics Relative Risk vs. Return Landscape

If you would invest  940.00  in Transcode Therapeutics on November 8, 2025 and sell it today you would lose (82.00) from holding Transcode Therapeutics or give up 8.72% of portfolio value over 90 days. Transcode Therapeutics is currently generating 0.0204% in daily expected returns and assumes 6.154% risk (volatility on return distribution) over the 90 days horizon. In different words, 55% of stocks are less volatile than Transcode, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Expected Return   
       Risk  
Given the investment horizon of 90 days Transcode Therapeutics is expected to generate 2.75 times less return on investment than the market. In addition to that, the company is 8.04 times more volatile than its market benchmark. It trades about 0.0 of its total potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.07 per unit of volatility.

Transcode Therapeutics Target Price Odds to finish over Current Price

The tendency of Transcode Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 8.58 90 days 8.58 
about 60.66
Based on a normal probability distribution, the odds of Transcode Therapeutics to move above the current price in 90 days from now is about 60.66 (This Transcode Therapeutics probability density function shows the probability of Transcode Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days Transcode Therapeutics has a beta of 0.34 indicating as returns on the market go up, Transcode Therapeutics average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Transcode Therapeutics will be expected to be much smaller as well. Additionally Transcode Therapeutics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial.
   Transcode Therapeutics Price Density   
       Price  

Predictive Modules for Transcode Therapeutics

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Transcode Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Hype
Prediction
LowEstimatedHigh
2.308.7515.20
Details
Intrinsic
Valuation
LowRealHigh
2.348.7915.24
Details
Naive
Forecast
LowNextHigh
0.266.7113.16
Details
1 Analysts
Consensus
LowTargetHigh
9.1010.0011.10
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Transcode Therapeutics. Your research has to be compared to or analyzed against Transcode Therapeutics' peers to derive any actionable benefits. When done correctly, Transcode Therapeutics' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Transcode Therapeutics.

Transcode Therapeutics Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Transcode Therapeutics is not an exception. The market had few large corrections towards the Transcode Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Transcode Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Transcode Therapeutics within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
-0.35
β
Beta against Dow Jones0.34
σ
Overall volatility
1.22
Ir
Information ratio -0.06

Transcode Therapeutics Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Transcode Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Transcode Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Transcode Therapeutics had very high historical volatility over the last 90 days
Transcode Therapeutics has high likelihood to experience some financial distress in the next 2 years
Net Loss for the year was (16.75 M) with profit before overhead, payroll, taxes, and interest of 0.
Transcode Therapeutics currently holds about 13.45 M in cash with (13.34 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.04.
Transcode Therapeutics has a frail financial position based on the latest SEC disclosures
Latest headline from news.google.com: Market Catalysts Is TransCode Therapeutics Inc a speculative investment - Quarterly Portfolio Report Fast Gain Swing Alerts - baoquankhu1.vn

Transcode Therapeutics Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Transcode Stock often depends not only on the future outlook of the current and potential Transcode Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Transcode Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding356.1 K
Cash And Short Term Investments5.8 M

Transcode Therapeutics Fundamentals Growth

Transcode Stock prices reflect investors' perceptions of the future prospects and financial health of Transcode Therapeutics, and Transcode Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Transcode Stock performance.

About Transcode Therapeutics Performance

Evaluating Transcode Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Transcode Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Transcode Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Return On Tangible Assets(2.64)(2.77)
Return On Capital Employed(3.98)(4.18)
Return On Assets(2.64)(2.77)
Return On Equity 9.54  10.02 

Things to note about Transcode Therapeutics performance evaluation

Checking the ongoing alerts about Transcode Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Transcode Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Transcode Therapeutics had very high historical volatility over the last 90 days
Transcode Therapeutics has high likelihood to experience some financial distress in the next 2 years
Net Loss for the year was (16.75 M) with profit before overhead, payroll, taxes, and interest of 0.
Transcode Therapeutics currently holds about 13.45 M in cash with (13.34 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.04.
Transcode Therapeutics has a frail financial position based on the latest SEC disclosures
Latest headline from news.google.com: Market Catalysts Is TransCode Therapeutics Inc a speculative investment - Quarterly Portfolio Report Fast Gain Swing Alerts - baoquankhu1.vn
Evaluating Transcode Therapeutics' performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Transcode Therapeutics' stock performance include:
  • Analyzing Transcode Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Transcode Therapeutics' stock is overvalued or undervalued compared to its peers.
  • Examining Transcode Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating Transcode Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Transcode Therapeutics' management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of Transcode Therapeutics' stock. These opinions can provide insight into Transcode Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Transcode Therapeutics' stock performance is not an exact science, and many factors can impact Transcode Therapeutics' stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.

Additional Tools for Transcode Stock Analysis

When running Transcode Therapeutics' price analysis, check to measure Transcode Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Transcode Therapeutics is operating at the current time. Most of Transcode Therapeutics' value examination focuses on studying past and present price action to predict the probability of Transcode Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Transcode Therapeutics' price. Additionally, you may evaluate how the addition of Transcode Therapeutics to your portfolios can decrease your overall portfolio volatility.